Free Trial

BeiGene (BGNE) Stock Forecast & Price Target

$154.26
+1.34 (+0.88%)
(As of 03:56 PM ET)

BeiGene - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 10 Wall Street analysts who have issued ratings for BeiGene in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 2 have given a hold rating, and 8 have given a buy rating for BGNE.

Consensus Price Target

$250.75
62.55% Upside
High Forecast$345.00
Average Forecast$250.75
Low Forecast$152.50

According to the 10 analysts' twelve-month price targets for BeiGene, the average price target is $250.75. The highest price target for BGNE is $345.00, while the lowest price target for BGNE is $152.50. The average price target represents a forecasted upside of 62.55% from the current price of $154.26.

TypeCurrent Forecast
7/18/23 to 7/17/24
1 Month Ago
6/18/23 to 6/17/24
3 Months Ago
4/19/23 to 4/18/24
1 Year Ago
7/18/22 to 7/18/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$250.75$251.93$251.70$278.43
Forecasted Upside62.55% Upside40.20% Upside38.99% Upside26.03% Upside
Get BeiGene Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter.

BGNE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BGNE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BeiGene Stock vs. The Competition

TypeBeiGeneMedical CompaniesS&P 500
Consensus Rating Score
2.80
2.71
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside63.97% Upside1,207.06% Upside7.63% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/9/2024Bank of America
4 of 5 stars
 Lower TargetNeutral ➝ Neutral$180.00 ➝ $152.50+5.82%
5/9/2024TD Cowen
4 of 5 stars
 Boost TargetBuy ➝ Buy$236.00 ➝ $254.00+51.95%
3/27/2024Sanford C. Bernstein
3 of 5 stars
 Lower TargetMarket Perform ➝ Market Perform$196.00 ➝ $161.00+4.67%
3/19/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$184.00 ➝ $186.00+10.79%
2/27/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$350.00 ➝ $345.00+98.62%
10/26/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$290.00 ➝ $285.00+72.27%
9/12/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$259.00+25.82%
9/11/2023Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$259.00+23.78%
8/29/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$321.00 ➝ $319.00+50.44%
8/17/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$287.00+49.22%
6/30/202351job
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/30/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/30/20233M
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
2/28/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$213.00 ➝ $262.00+21.28%
1/20/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$236.00 ➝ $300.00+9.29%
1/11/2023Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$308.00+20.87%
11/10/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$200.00 ➝ $213.00+13.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:28 PM ET.

BGNE Forecast - Frequently Asked Questions

What is BeiGene's forecast for 2024?

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for BeiGene is $250.75, with a high forecast of $345.00 and a low forecast of $152.50.

Should I buy or sell BeiGene stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BGNE shares.

Does BeiGene's stock price have much upside?

According to analysts, BeiGene's stock has a predicted upside of 39.96% based on their 12-month stock forecasts.

What analysts cover BeiGene?

BeiGene has been rated by research analysts at Bank of America, and TD Cowen in the past 90 days.

Do Wall Street analysts like BeiGene more than its competitors?

Analysts like BeiGene more than other "medical" companies. The consensus rating score for BeiGene is 2.80 while the average consensus rating score for "medical" companies is 2.71. Learn more on how BGNE compares to other companies.


This page (NASDAQ:BGNE) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners